We have examined the expression of the Leu-4 (T3) antigen on the cell surface and in the cytoplasm of blast cells from 23 patients with T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma. In the majority of cases (17) 
Introduction
Studies of immunologic membrane markers of malignant cells from human lymphoid leukemias and lymphomas have revealed the heterogeneous nature of these diseases. The majority of these malignancies now are known to be neoplasms that originate in cells at various stages of maturation in T or B lineage (1) (2) (3) (4) (5) (6) . Analysis of cases of T lineage malignancy with a series of monoclonal antibodies has provided important insights into the heterogeneity within the subset of T cell lymphoproliferations (7) (8) (9) (10) (11) (12) (13) . These studies of malignant cells in conjunction with studies of normal lymphocytes of T cell lineage from peripheral blood, thymus, and other tissues have added considerably to our understanding of normal T cell ontogeny. A model for T cell maturation has been proposed based upon these studies in which the stages of T cell maturation are characterized by profound changes in cell surface antigen expression (7, 9, 10) . According to this model, cells at the earliest stage of T cell ontogeny (which express the T9 and TIO antigens) acquire the thymocyte-specific antigen, (T6), as well as "helper" and "suppressor" antigens (Leu-3 and Leu-2 [T4, T51) with further maturation to the "cortical thymocyte" stage. The segregation of T cells into helper (Leu-2-/Leu-3+) and cytotoxic/suppressor (Leu-2+/Leu-3-) populations occurs in the late stages of intrathymic maturation as cells acquire antigenic profiles which resemble the phenotypes of mature T cells found in the peripheral blood compartment. A feature of this model of T cell ontogeny is that (T3), a pan-T antigen found on mature T cells, is not expressed until the late thymocyte stage when T cell subset commitment is established.
Support for this model of T cell maturation derives from studies of T lymphoblastic malignancies (T cell acute lymphoblastic leukemia [T-ALL]' and T cell lymphoblastic nonHodgkin's lymphoma [T-NHL]), which are presumed to arise from immature T cells. The majority (although not all) of cases studied demonstrate surface antigenic profiles consistent with the proposed stages of T cell maturation, thus supporting the concept that malignant cells in these lymphoproliferations represent the progeny of a transformed cell frozen at one point in normal cellular differentiation. As predicted by the model, blast cells from the majority of cases of T lymphoblastic malignancies do not express the Leu-4 antigen (7-13); thus, the majority of cases of T-ALL and T-NHL are presumed to arise from early and mid-thymocytes.
We have examined cases of T lymphoblastic malignancies for surface as well as cytoplasmic expression of T cell antigens, and we have found a discordance between surface and cytoplasmic expression of the Leu-4 antigen. As in previous reports, the antigen is absent, or weakly expressed, on the cell surface in the majority of cases. However, in virtually all cases of T-ALL and T-NHL, intracellular antigen is found in blast cells even when the antigen is absent from the cell surface.
Methods
Monoclonal antibodies. Monoclonal antibodies Leu-1 (Pan-T), Leu-2a (T cytotoxic/suppressor), Leu-3a (T helper), Leu-4 (Pan-T), Leu-5 (E rosette receptor), (thymocyte), Leu-9 (T-ALL/NHL), Leu-12 (B cell), HLA-DR, and CALLA (common acute lymphoblastic leukemia antigen) were generously supplied by the Becton-Dickinson Monoclonal Center (Mountain View, CA). Monoclonal antibodies OKT9 (transferrin receptor) and OKT10 were purchased from Ortho Pharmaceuticals (Raritan, NJ). Monoclonal antibody Bl was purchased from Coulter Laboratories (Hialeah, FL). The methods of development of these reagents and the distribution of the antigens detected by these reagents on normal tissues and malignant cells have been reported previously (7, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
Patients and cells. Malignant cells were obtained from patients at the time of initial presentation or relapse after informed consent was obtained. Tissue analyzed included lymph nodes, pleural effusions, bone marrow, and peripheral blood. Only specimens containing >80% malignant cells were analyzed. The diagnosis in each case was established by standard morphologic and histochemical parameters. Normal thymus glands were obtained from fresh surgical specimens.
Immunophenotyping studies were performed on cells in single-cell suspension and also in tissue section. Cell suspensions were made from leukemia and lymphoma cells which were isolated from heparinized bone marrow, peripheral blood, and malignant effusions by FicollHypaque density sedimentation. Single-cell suspensions were also made from lymphomatous masses and lymph nodes which were gently teased and passed through a stainless steel mesh. In the majority of cases, immunophenotyping studies were performed on cell suspensions when first obtained, but in some cases immunophenotype analysis was performed on cells cryopreserved by using standard techniques and stored at -1960C in 10% dimethylsulfoxide and 10% fetal calf serum. There was no difference in cell surface markers when performed sequentially on fresh and frozen cells.
The cell lines 255.88 (22) (a T-T hybrid line) and HPB-ALL (23) were utilized in these studies. Characteristics of these lines have been previously described.
Immunophenotyping studies. Cell surface antigens were identified by the binding of monoclonal antibody detected by indirect immunofluorescence. One million cells were placed in plastic tubes and incubated with 1 gg of purified monoclonal antibody at 40C for 20 min. Cells were washed twice in the cold in phosphate-buffered saline plus 0.02% sodium azide to remove excess antibody, and incubated for 20 min at 40C with fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin (Tago Inc., Burlingame, CA). The cells were washed twice, fixed in 1% formaldehyde in phosphate-buffered saline, and analyzed for fluorescence staining with a fluorescenceactivated cell sorter equipped with a log amplifier (FACS IV, Becton, Dickinson Electronics Laboratory, Mountain View, CA) interfaced with a Consort 440 computer system. The intensity of fluorescence for 10,000 cells in each sample was determined and the results were displayed as a histogram by plotting the fraction of total cells versus intensity of fluorescence for each antibody. Background fluorescence was determined by incubating the cells with a nonreactive myeloma protein in place of specific antibody. The cell population from an individual patient was felt to be reactive with an antibody if >20% of cells demonstrated specific fluorescence when compared with the background control.
Immunologic phenotyping of frozen tissue sections was performed by utilizing a biotin-avidin-horseradish peroxidase technique, as previously reported (24). Representative portions of fresh surgical biopsy specimens were snap-frozen, sectioned, and acetone-fixed before staining. The frozen sections were sequentially stained with unconjugated monoclonal antibody followed by biotinilated goat anti-mouse IgG (Tago Inc.) or horse anti-mouse IgG (Vector Laboratories, Inc., Burlingame, CA) followed by avidin-horseradish-peroxidase conjugate (Vector Laboratories). Individual cells were identified on the basis of characteristic histologic features and antigen expression. As in the cell suspension studies, isotype-matched nonreactive myeloma proteins were used as controls for background staining.
Cytocentrifuge preparations were prepared from the single-cell suspensions by utilizing a Shandon cytocentrifuge ( 10 Mg, and goat anti-mouse IgG (EY Labs, San Mateo, CA) at 4°C over 6 h while slowly rotating. Specific immunoprecipitation, using 10 ,g of specific, purified, anti-Leu-4 antibody and goat antimouse IgG at equivalence, was performed in a similar fashion over 18 h. Precipitates were collected by centrifugation and washed six times in NaCl-EDTA-Tris buffers containing NaCl 0.15 M, EDTA 5 mM, Tris-HCI 50 mM, pH 7.4, Na azide 0.02%, NP-40 decreasing from I to 0%, and additional NaCI to 0.5 M in the first four washes. One-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of samples was carried out on 10% acrylamide gels as described previously by Laemmli (29).
Results 10 cases of T cell acute lymphoblastic leukemia and 13 cases of T cell lymphoblastic lymphoma were studied for both surface and cytoplasmic antigen expression. In all cases, the diagnosis was confirmed by examination of appropriately stained tissue by utilizing standard morphologic criteria. The T cell lineage of these malignancies was confirmed by the reactivity of blast cells with one or more T lineage antibodies. In all 22 cases tested, blast cells were reactive with anti-Leu-9. We and others have shown previously that expression of the 40,000 mol wt antigen defined by Leu-9 (4H9) (13) or its equivalents (WTI [30], 3A1 [31] ) reliably confirms T cell lineage among the childhood lymphoblastic leukemias and lymphomas.
Results of surface immunophenotyping of malignant cells in suspension are shown in Table I . As in other series of T-ALL and T-NHL, the majority (17 of 23) of cases were Leu-4 negative. In all Leu-4-negative cases, <15% of cells expressed the Leu-4 antigen, and among the Leu-4-positive cases, expression of material had a molecular weight of 2. described (32) . Moreover, by one analysis, the major polypeptide fami cipitated from the two cell lines al Over the 2-h labeling period, as m reactive material was synthesized by surface Leu-4 negative.
Discussion
The Leu-4 (T3) antigen consists of molecules of -25,000 mol wt on th blood T cells and 30-60% of thymo found on the surface of leukocytes ( The absence of this molecule on th of thymocytes and the majority T-NHL, which are presumed to be has led investigators to conclude the restricted to mature thymocytes and In this report, 23 cases of T-ALI studied for surface as well as intrace 4. As in other series, we found t] majority (74%) of cases of T-ALL ank the Leu-4 antigen on the cell surf demonstrated a discordance between expression of Leu-4 in T lymphoblas dance in results of testing for Leu-4 b cells was found in 16 of 23 case4 discordance rate of only 7% for a Moreover, six of the cases studied we no discordance could be detected. (27, 28 (40) have demonstrated that rearrangements of the gene for the T cell receptor occurs in immature cells of T lineage that express the mid-and late-thymocyte phenotype, although not in cells that express the early thymocyte phenotype. Apparently, rearrangement of the T cell receptor gene occurs early (if not at the earliest stage) in T cell ontogeny. Our studies indicate that synthesis of the Leu-4 antigen, a molecule which is critical to the function of the mature T-cell, likewise occurs in immature T cells, and may precede the rearrangement of the T cell receptor gene inasmuch as the Leu-4 antigen can be found in cells expressing even the most immature thymocyte phenotype.
The pivotal role of the Leu-4 antigen in the function of the mature T cell is now recognized. Recent studies have demonstrated that the T cell receptor is noncovalently linked to Leu-4 (T3) on the cell surface (41-43). Moreover, experiments that utilize mutants of the Jurkat T cell leukemia line (44) suggest an intimate interdependence in the surface expression of the Leu-4 and T receptor molecules; surface expression of neither of these molecules occurs without co-expression of the other. In that the Leu-4 antigen is not expressed on the cell surface until late in T cell ontogeny, antigen specificity is not conferred upon the maturing T cell until late in T cell development. From our study, it is apparent that the Leu-4 molecule can be demonstrated intracellularly early in T cell ontogeny. Because the intracellular Leu-4 antigen is apparently similar to the surface-expressed polypeptide, it is not clear why expression is restricted to the cytoplasm. It is possible that synthesis of the Leu-4 antigen precedes the synthesis of at least part of the T cell receptor heterodimer in T cell ontogeny. As in the pre-B cell where the immunoglobulin heavy chain is restricted to the cytoplasm until light chain synthesis occurs (45), the surface Leu-4-/cytoplasmic Leu-4+ T cell leukemias may represent an early stage of T cell development where the Leu-4 portion of the T cell receptor complex is restricted to the cytoplasm before synthesis of the T cell receptor heterodimer. Studies are now underway to test this hypothesis.
